Browsing Tag
Nav1.7
2 posts
Sangamo Therapeutics wins FDA fast-track status for gene therapy ST-503 targeting small fiber neuropathy
Find out how Sangamo Therapeutics’ FDA fast-track win for ST-503 could reshape small fiber neuropathy treatment and shift biotech investor sentiment.
Will ST‑503 be the non‑opioid breakthrough in pain therapy? Sangamo gets Fast Track nod
Sangamo Therapeutics gains FDA Fast Track for ST-503, a gene therapy targeting chronic neuropathic pain. Find out what this means for non-opioid innovation.